Urgent.News

What's breaking now, across thousands of outlets.

More in Finance & Markets

Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027

One of these mRNA pioneers has the products and pipeline to drive growth.

  • Moderna and BioNTech transitioned beyond coronavirus vaccines in 2026
  • BioNTech's future depends on CEO and CMO leadership transition by Feb 1
  • Moderna has commercialized flu vaccine and advancing intismeran in oncology

More from Friday 20 November →